Drug Profile

Rotavirus vaccine - MAXVAX Biotechnology

Latest Information Update: 28 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator MAXVAX Biotechnology
Class Rotavirus vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Rotavirus infections

Most Recent Events

28 Jan 2026 No recent reports of development identified for clinical-Phase-Unknown development in Rotavirus-infections(In neonates, Prevention) in Australia (Parenteral)
14 Dec 2022 MAXVAX Biotechnology plans for launch of Rotavirus vaccine in 2025 (MAXVAX Biotechnology pipeline, December 2022)
14 Dec 2022 MAXVAX Biotechnology plans for NDA filling for Rotavirus vaccine in 2024 (MAXVAX Biotechnology pipeline, December 2022)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com